II期结肠癌的基因特征：临床综述
Gene Signatures in Stage II Colon Cancer: A Clinical Review.
作者信息
Sharif Saima, O'Connell Michael J
机构信息
National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA ; Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA.
出版信息
Curr Colorectal Cancer Rep. 2012 Sep;8(3):225-231. doi: 10.1007/s11888-012-0132-7.
Understanding the biology of cancer is the key to understanding its behavior. Stage II colon cancers represent a unique treatment challenge for medical oncologists because they contain a very heterogeneous group of tumors with a wide range of recurrence risks after resection. Defining these differences in biology can help to explain differences in behavior. To this end, gene signatures have been developed to define various prognostic groups beyond the clinicopathologic features alone. Adjuvant chemotherapy for stage II colon cancers as a group has not shown survival advantage in clinical trials. Future research to develop gene signatures to predict a group that will benefit from adjuvant chemotherapy will be helpful in the clinical decision-making process. The purpose of this review is to present the prognostic gene signatures currently available for use, those in development, and their utility in stratifying recurrence risk in stage II colon cancer patients.
了解癌症生物学是理解其行为的关键。II期结肠癌对肿瘤内科医生来说是一个独特的治疗挑战，因为它们包含一组非常异质性的肿瘤，切除后复发风险范围很广。明确这些生物学差异有助于解释行为上的差异。为此，已经开发了基因特征来定义除临床病理特征之外的各种预后组。作为一个整体，II期结肠癌的辅助化疗在临床试验中并未显示出生存优势。未来开展研究以开发基因特征来预测能从辅助化疗中获益的人群，将有助于临床决策过程。本综述的目的是介绍目前可用的、正在开发的预后基因特征，以及它们在II期结肠癌患者复发风险分层中的作用。
Zotero 插件